We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.175 | -4.12% | 4.075 | 4.00 | 4.15 | 4.25 | 4.075 | 4.25 | 1,068,871 | 11:57:45 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.83M | -2.24M | -0.0042 | -11.90 | 26.67M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/10/2021 13:31 | Yes I've read it. | timbo_slice | |
20/10/2021 12:43 | Timbo, Learn to read. From the recent Annual Report "Eden remains debt-free and has a strengthened balance sheet allowing us to execute on our exciting plans." AND from today's RNS "Trading on the U.S. OTC market has no impact on existing Eden ordinary shares trading on the AIM market of the London Stock Exchange and no new ordinary shares will be issued as part of the cross-trade." | investingisatrickygame | |
20/10/2021 12:04 | Always said a fundraising /dilution | timbo_slice | |
20/10/2021 11:21 | Timbo_Slice 20 Oct '21 - 08:43 - 10821 > Helps with a fundraising though :) Ah, you changed your meds. Good show. One issue; you misspelled "dilution" as "fundraising". Restated target SP: ZERO PENCE (0.0p) | neutralpov | |
20/10/2021 11:06 | Apologies - internet issues - repeated posting. | erinvale1 | |
20/10/2021 11:06 | Apologies - internet issues - repeated posting. | erinvale1 | |
20/10/2021 11:05 | Repeatedly. He has nothing to say on this issue and comes over as having a 'big corporate' mindset - hence the massive, glossy (and costly) annual repors - 2020 106 pages, 2019 - 100 pages - and this for a company turning over GBP 2 million (2020), GBP 1.2 million (2019). Apart from the egregious waste of shareholders funds, this says much about Sean Smith's view of Eden as a big player in the sustainable agri market. The reality is that it is nothing more than a hawker in an up-market shopping mall. | erinvale1 | |
20/10/2021 09:14 | Spadey: There is no connection I can see between OTC market trading approval and US EPA approval. This is purely related to a share trading facility. Also, while EPA approval certainly opens up opportunity for US sales, like most of Eden's multitude of earlier such approvals, it doesn't mean that sales will materialise. This is precisely my point: endless tie-ups, distribution agreements, approvals, but negligible sales. Eden needs to focus on sales, not waste funds it does not have on laboratories etc. Sean Smith has no sales strategy except for hope that the company's distribution agreements will deliver. If the past is anything to go by, they won't. | erinvale1 | |
20/10/2021 08:43 | Helps with a fundraising though :) | timbo_slice | |
20/10/2021 08:25 | Today's RNS - Eden admitted to US OTC market. More process. This won't generate a cent of sales. When will Sean Smith and his over-paid colleagues understand that the company needs sales to survive? | erinvale1 | |
19/10/2021 19:57 | Shut up, chops, and get out. Likewise anyone else bringing up off-topic carp over here. The subject is EDEN.L SELL HOLD BUY Geddit? FFS. | neutralpov | |
19/10/2021 15:11 | Sorry didn't mean to burden you all with that. I will not post again. Just remember 140,000 uk citizens have lost their lives to COVID. You guys have lost a few quid on Eden. Take a balanced view of life. | ravenna23 | |
19/10/2021 14:38 | Tricky, my sister was murdered and my brother electrocuted before I was twelve. Maybe you should think before you wish tragedy on others. Just saying. | ravenna23 | |
19/10/2021 14:24 | I must have been very good! | ravenna23 | |
19/10/2021 11:43 | NPOV/the white house.....plant impact, says it all really. | tanners |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions